Finance
Ceplene maker reports net loss for first quarter
Published in Hepatitis Weekly, March 1st, 2004
The net loss applicable to common stock for the first quarter totaled $9.9 million, or $0.35 per share, compared to a loss applicable to common stock of $9.3 million, or $0.40 per share, for the same period of the prior year. The current-quarter increase in net loss primarily resulted from the company's ongoing research and development activities, which included the recent regulatory filing for European approval to market Ceplene.
At December 31, 2003, the company had cash, cash equivalents, and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-03-01)
More Articles from Hepatitis Weekly
- Chemotherapy
Lamivudine maintains adriamycin intensity in hepatitis B patients with lymphoma - Psychology
Hepatitis C virus-infected patients with depression tolerate citalopram - Adverse Drug Effects
APOE genotypes may influence a person's response to interferon-alpha - Fatty Liver
Genotype 3 increases the risk for steatosis in those infected with hepatitis C - Proteomics
A newly discovered mimotope could lead the way to HCV receptor antagonism - Public Health
Brazilian ex-soccer players may have spread hepatitis C with shared needles - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
